Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-059332
Filing Date
2021-11-15
Accepted
2021-11-15 16:05:37
Documents
90
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_immucellcorp.htm   iXBRL 10-Q 1110590
2 CERTIFICATION f10q0921ex31_immucellcorp.htm EX-31 6814
3 CERTIFICATION f10q0921ex32_immucellcorp.htm EX-32 4717
  Complete submission text file 0001213900-21-059332.txt   6350529

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20210930.xsd EX-101.SCH 73427
5 XBRL CALCULATION FILE iccc-20210930_cal.xml EX-101.CAL 30884
6 XBRL DEFINITION FILE iccc-20210930_def.xml EX-101.DEF 290712
7 XBRL LABEL FILE iccc-20210930_lab.xml EX-101.LAB 579794
8 XBRL PRESENTATION FILE iccc-20210930_pre.xml EX-101.PRE 307799
9 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_immucellcorp_htm.xml XML 894500
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 211410333
SIC: 2835 In Vitro & In Vivo Diagnostic Substances